Considering that we observed attenuation of the p53 pathway in BCP-ALL cells subjected to VEN treatment, we next aimed to elucidate if the status of p53 affects the efficacy of the combination of VEN+AUR. This evidence concerns the gene TP53 and acute lymphoblastic leukemia.